Talaris Therapeutics: Funding, Investors & Team (Sep 2026)
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.
Talaris Therapeutics has raised $115M across 1 funding round on record, the most recent an undisclosed round of $115M announced in Oct 2020.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Talaris Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2020.
Talaris Therapeutics Funding Rounds
Talaris Therapeutics Founders and Leadership Team
Contact details for the Talaris Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Talaris Therapeutics Funding Compared to Other Biotechnology Startups
Talaris Therapeutics' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Talaris Therapeutics in Biotechnology and Wellesley
Companies Similar to Talaris Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Talaris Therapeutics Funding FAQs
What does Talaris Therapeutics do?
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.
How much funding has Talaris Therapeutics raised?
Talaris Therapeutics has raised $115M across 1 round on record. The most recent is an undisclosed round of $115M announced in Oct 2020.
When did Talaris Therapeutics last raise funding?
Talaris Therapeutics' most recent funding round on record is an undisclosed round of $115M, announced in Oct 2020.
Who is the CEO of Talaris Therapeutics?
Scott Requadt is listed as CEO at Talaris Therapeutics.
Where is Talaris Therapeutics headquartered?
Talaris Therapeutics is based in Wellesley, Massachusetts, United States.
How many employees does Talaris Therapeutics have?
Talaris Therapeutics is in the 51-100 employee band.
How does Talaris Therapeutics' funding compare to other Biotechnology startups?
Talaris Therapeutics' latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Talaris Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Talaris Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.